Combined Inhibition of Gα q and MEK Enhances Therapeutic Efficacy in Uveal Melanoma

All uveal melanoma and a fraction of other melanoma subtypes are driven by activation of the G-protein alpha-q (Gα ) pathway. Targeting these melanomas has proven difficult despite advances in the molecular understanding of key driver signaling pathways in the disease pathogenesis. Inhibitors of Gα have shown promising preclinical results, but their therapeutic activity in distinct Gα mutational contexts and have remained elusive. We used an isogenic melanocytic cellular system to systematically examine hotspot mutations in (e.g., G48V, R183Q, Q209L) and (L129Q) found in human uveal melanoma. This cellular system and human uveal melanoma cell lines were used and in xenograft studies to assess the efficacy of Gα inhibition as a single agent and in combination with MEK inhibition. We demonstrate that the Gα inhibitor YM-254890 inhibited downstream signaling and growth in all mutants. , YM-254890 slowed tumor growth but did not cause regression in human uveal melanoma xenografts. Through comprehensive transcriptome analysis, we observed that YM-254890 caused inhibition of the MAPK signaling with evidence of rebound by 24 hours and combination treatment of YM-254890 and a MEK inhibitor led to sustained MAPK inhibition. We further demonstrated that the combination caused synergistic growth inhibition and tumor shrinkage . These data suggest that the combination of Gα and MEK inhibition provides a promising therapeutic strategy and improved therapeutic window of broadly targeting Gα in uveal melanoma. .